Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 10/20 | 0.47 |
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA12 | O43570 | 8/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614200 | 1.00 | LMNA (0.51) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL12892515 | 1.00 | LMNA (0.51) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL15031303 | 1.00 | LMNA (0.51) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL12154623 | 0.90 | CD69 (0.44) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL12879162 | 0.90 | LMNA (0.40) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL12150456 | 0.90 | LMNA (0.40) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL28449032 | 0.84 | LMNA (0.55) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL14036675 | 0.84 | LMNA (0.34) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL16349578 | 0.84 | OGA (0.36) | LMNAALDH1A1THRBSMN1; SMN2HIF1A | |
| SCHEMBL5566952 | 0.83 | LMNA (0.52) | LMNAALDH1A1THRBSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005067982-A2 | METHODS FOR IMAGING THE LYMPHATIC SYSTEM USING DENDRIMER-BASED CONTRAST AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050159372-A1 | Nucleoside analogs with carboxamidine modified monocyclic base | VALEANT CANADA LP (CA) | 2005-07-21 | — | — | US | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096233-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040014696-A1 | Specificity in treatment of diseases | VALEANT RESEARCH & DEVELOPMENT | 2004-01-22 | — | — | US | disclosed |
| US-4992426-A | Antiparasitic 5'-sulfamoyl nucleosides | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1991-02-12 | — | — | US | disclosed |
| US-4925930-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1990-05-15 | — | — | US | disclosed |
| US-RE29835-E | PHARMACEUTICAL | ICN PHARMACEUTICALS (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LMNA 2918/4885ALDH1A1 4754/4885THRB 4066/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LMNA 2918/4885ALDH1A1 4754/4885THRB 4066/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LMNA 2918/4885ALDH1A1 4754/4885THRB 4066/4885 |
| US-20040014696-A1 | Specificity in treatment of diseases | GLS2, GOT2, SHMT2 | LMNA 1844/4885ALDH1A1 1004/4885THRB 1665/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | LMNA 2901/4885ALDH1A1 3720/4885THRB 3649/4885 |
| US-20050159372-A1 | Nucleoside analogs with carboxamidine modified monocyclic base | NT5C2, PNP, SLC29A1 | LMNA 3406/4885ALDH1A1 1998/4885THRB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.